UPDATE: Jefferies Starts Prelude Therapeutics (PRLD) at Buy; Three Shots on Goal Forthcoming
Tweet Send to a Friend
(Updated - July 29, 2022 8:06 AM EDT)
Jefferies analyst Roger Song initiates coverage on Prelude Therapeutics (NASDAQ: PRLD) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Jefferies analyst Roger Song initiates coverage on Prelude Therapeutics (NASDAQ: PRLD) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
